TCTR20221104006Unknown1 期
A Bioequivalence Study of Two Formulations of 20-mg Rabeprazole Sodium Gastro-resistant Tablets in Healthy Thai Subjects under Fed Conditions
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Thai Male/Female must be 18-55 years of age, body mass index (BMI) = 18.0-30.0 kg/m2, inclusive. 2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 or not over 129 mmHg, diastolic blood pressure not lower than 60 or not over 79 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians 3. Screening electrocardiogram (ECG) without clinically significant abnormalities 4. Screening visit laboratory values of blood test including hematology (complete blood count (CBC) with differential), fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine (Cr), and liver function test (aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin and alkaline phosphatase (ALP)) must be within the normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians. 5. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians. 6. Must have serum hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) seronegative 7. Female subjects must have beta-subunit of human chorionic gonadotropin in serum (beta-hCG) negative. 8. Female subject who is childbearing potential or male subject agrees to use an acceptable birth control method from visit 1 to the follow-up visit. The acceptable birth control method is defined as a barriermethod of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow-up visit. Hormonal contraceptives are not acceptable. 9. Female subject who is non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)) 10. Female subjects must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at Period 1, Period 2, Period 3 and Period 4. 11. Non-smokers (never smoked or no smoking within the previous 1 year) 12. Refrain from using herbal medications, cannabis containing products, dietary supplements (e.g., St. Johns Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of investigational product (Day 1). Subjects must agree to refrain from these items until the last collection time-point of Period 4. 13. Subjects must have ended any medications at least 30 days prior to Day 1 or at least 5 times of elimination half-life prior to Day 1 and agree to continue their refraining throughout the follow-up period. 14. Subject does not receive Coronavirus Disease-19 (COVID-19) vaccine within 14 days before screening visit and does not plan to receive COVID-19 vaccine until the follow-up period. 15. Subjects must refrain from drinking caffeine and alcohol for at least 72 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of Period 4. 16. Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Institutional
排除标准
- •1. Known hypersensitivity to rabeprazole, any other similar class of drugs or its components
- •2. Past medical history of renal and hepatic insufficiency
- •3. Subject has a history of any illness that, in the opinion of Principal/Clinical Investigator or designated physicians, might confound the result of the study or pose an additional risk in administering investigational product to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
- •4. Have history of drug abuse (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
- •5. Have positive result of urine drug abuse testing on opioids (morphine (Mor), methadone (MTD)), cannabinoids (tetrahydrocannabinol (THC)), methamphetamine (Meth), cocaine (Coc) and methylenedioxy-methamphetamine (MDMA) at screening visit or before dose administration at each period
- •6. Alcohol abuse or excessive use (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
- •7. Have positive result of alcohol breathing test at screening visit or before dose administration at each period
- •8. Female subject is pregnant or breast feeding.
- •9. Difficulties fasting or consuming a high-fat high-calories standard meals
- •10. Difficulties swallowing whole tablets
- •11. Donation or loss of whole blood.
- •12. Participation in any investigational drug study within 30 days prior to screening visit (from the last follow-up visit to the screening visit). Subject who participates in COVID-19 vaccine trial that does not have any intervention during the course of this study (from the expected enrollment date to the expected follow-up visit) can be included in this study.
研究者
相似试验
Unknown
1 期
A Bioequivalence Study of Two Formulations of 20-mg Rabeprazole Sodium Gastro-resistant Tablets in Healthy Thai Subjects under Fasting ConditionsGERD, heartburn symptoms, duodenal ulcers, hypersecretory conditions, Zollinger-Ellison SyndromeGERD, Ulcer, Zollinger-Ellison SyndromeTCTR20221104001KOREA UNITED PHARM. INC.30
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 20-mg Rivaroxaban Tablets in Healthy Thai Volunteers under Fed ConditioHealthy volunteersBioequivalenceRivaroxabanPharmacokinetic studyTCTR20200513006ovartis (Thailand) Ltd.40
已完成
1 期
A Bioequivalence Study of Two Formulations of 20-mg Rivaroxaban Tablets in Healthy Thai Volunteers under Fed ConditioBioequivalenceHealthy volunteersRivaroxabanPharmacokinetic studyTCTR20190503001ovartis (Thailand) Ltd.24
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 25 mg Pregabalin Capsules in Healthy Thai Volunteers under Fasting Conditionshealthy volunteerPregabalin BioequivalenceTCTR20230208004Faculty of Medicine Siriraj Hospital28
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 25-mg Empagliflozin Tablets in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20221003003Siriraj Institute of Clinical Research (SICRES)28